Study Finds Evidence Of Higher Consciousness From Psychedelics
Scientists have found the first evidence of a higher state of consciousness by measuring the complexity of brain activity of people under the influence of psychedelics. The study measured magnetic fields generated by brain activity and used the data to create an index of varying levels of consciousness.
The study, conducted by a team at the University of Sussex in England, looked at the diversity of brain signals, a measure of the complexity of brain activity, in people under the influence of psilocybin, LSD, and ketamine, compared to the brain activity of people in lower levels of consciousness, such as sleep, anesthesia, and ‘vegetative’ states.
Participants under the influence of these drugs showed higher than baseline diversity, or higher levels than someone who is simply awake. This is the first time a measure of an elevated consciousness has been recorded in a study of its kind.
The researchers were quick to point out that their measure of higher consciousness doesn’t necessarily imply that the psychedelic state is better or higher functioning than our normal waking state. Instead the index they’ve used shows that the psychedelic state increases small magnetic fields produced by the brain and higher neural-signal diversity in all three types of drugs.
According to the study, “During the psychedelic state, the electrical activity of the brain is less predictable and less ‘integrated’ than during normal conscious wakefulness.”
One researcher involved in the study, Dr. Muthukumaraswamy, said he was surprised the results were consistent with each drug, despite their differing pharmacology. He and his colleagues believe that their research could lead to carefully-controlled use of the drug for therapeutic treatment in patients suffering from severe depression.
The group found correlation between participants’ reports of changes in intensity of the psychedelic experience and changes in brain signal diversity. They believe this shows there is a difference in aspects of brain activity in our everyday conscious experience.
This study comes after recent trials have shown psilocybin can flip a “reset” mechanism in the brains of people suffering from depression. Similar studies found benefits in the therapeutic use of ketamine and LSD for people suffering from a range of physical and psychiatric issues, including drug addiction and PTSD.
Similar studies have been conducted to test electroencephalography, or EEG, on participants in deep states of meditation, finding increased levels of alpha and theta wave activity. It’s unclear whether this recent study plans on testing participants levels of brain-signal diversity in non-intoxicated, altered states of consciousness.
DMT: Revolution of Consciousness
About the Author
New Studies Find Psychedelics Highly Effective for Alcoholism
New studies show unprecedented success in the treatment of alcoholism with psychedelic therapy.
The psychedelic revolution in mental health has produced overwhelming scientific evidence demonstrating the great efficacy of psychedelics in the treatment of various mental health disorders. Now, several new studies involving the drugs ketamine and MDMA are showing significant promise in the treatment of alcoholism.
Dr. Ben Sessa is a psychiatrist and chief medical officer at Awakn Life Sciences, an English biotech company that is at the forefront of the research, development, and delivery of psychedelic medicines.
The company is especially focused on the treatment of Alcohol Use Disorder or AUD, given how prevalent and challenging it is to treat.
“Alcoholism is a huge public health problem. It’s also a psychiatric condition that’s very poorly treated with very poor outcomes with traditional methods,” Sessa said. “Relapse to drinking after getting dry is around 80 to 90 percent at 12 months. That’s an embarrassingly poor statistic. Psychedelics offer a completely new approach; they offer the patient to explore the root causes of addiction, which so often is trauma. Psychedelic-assisted psychotherapy is an intensive upfront piece of work that gets the patient better, so they don’t have to keep coming back. It is a completely different paradigm shift to the way we currently manage patients in maintenance therapies.”
A recent study conducted by researchers at the University of Exeter and Awakn Life Sciences is the world’s first to examine the use of ketamine to treat AUD in a randomized controlled trial.
“Ketamine is a very well-established human medicine. It is indeed the only psychedelic that’s licensed as a medicine, as an anesthetic medicine, and has been used since the 60s as such. It’s an incredibly safe medicine. When it’s used at a much lower dose, it produces an altered state of consciousness. What we do in psychedelic-assisted psychotherapy with ketamine, is we use this altered state of consciousness to affect a more effective and deeper form of psychotherapy. So, we’re using ketamine as an adjunct to psychotherapy to treat addictions,” he said.
